Key result
Study evaluates inotersen for the treatment of ATTR cardiomyopathy.
Key points are not available for this paper at this time.
Inotersen evaluation in ATTR cardiomyopathy should not yet change practice; leaves open efficacy and safety pending randomized trials.
"Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen." Amyloid, 26(sup1), pp. 20–21
No takes yet. Share an insight, caveat, or question.
Dasgupta et al. (2019) studied this question. Inotersen, a TTR-specific antisense oligonucleotide, was evaluated for the treatment of ATTR cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: